Three-drug combinations have been shown to improve outcomes over two-drug combinations in patients with multiple myeloma. Three-drug combinations are more likely to generate a response, slow disease progression, and extend survival. Because of these benefits, triplet combinations are currently considered the standard therapeutic regimen. Patients who are not initially candidates for a three-drug regimen can receive a two-drug regimen and have the third drug added once their performance status improves.
There is currently no treatment that can prevent monoclonal gammopathy of undetermined significance from progressing into multiple myeloma. Blood tests may be performed to check for signs of progression.
Adjunctive therapies that may be used in multiple myeloma include plasmapheresis, erythropoietin-stimulating agents, corticosteroids, radiation therapy, and surgical intervention.
Learn more about multiple myeloma therapies and outcomes.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Joshua Richter. Fast Five Quiz: Multiple Myeloma Management - Medscape - May 13, 2021.
Comments